Crofelemer has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency for SBS and MVID. In October 2025, as announced, the company ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment ...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are accelerating market growth, with the genomics in cancer care market ...
Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failureAssociated ...
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of ...
19hon MSN
A CT hospital is expanding a program that is saving lives. Here’s how it works, why it was adopted
Use of whole blood products to save egregiously injured U.S. military combatants became a practice during wars in Iraq and ...
Jaguar Health (JAGX) announced that an article published December 29, 2025 in HEALTH, a bi-monthly English and Arabic healthcare magazine in the ...
Positive full results from AstraZeneca’s Phase III TULIP-SC trial have shown the subcutaneous (SC) administration of Saphnelo ...
While Zenas’ obexelimab hit the primary endpoint in the Phase III INDIGO study, it came far below the efficacy threshold set ...
This guide deconstructs the pathophysiology of UTIs, exploring the anatomical risks in women, and the efficacy of antibiotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback